Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$1.05
-2.8%
$1.18
$0.77
$637.25
$3.09M2.67681,644 shs259,266 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.10
-4.3%
$1.15
$0.95
$5.99
$13.01M1.2963,562 shs48,971 shs
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
$6.52
-3.3%
$5.30
$2.12
$12.72
$12.26M0.26350,730 shs17,496 shs
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
$0.63
-5.6%
$0.67
$0.48
$3.55
$11.45M0.86923,575 shs64,611 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-2.78%-13.93%0.00%-56.61%-99.80%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-4.35%0.00%-12.70%-27.87%-72.01%
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
-3.26%+17.90%+20.96%+25.63%+651,999,900.00%
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
-5.57%-18.31%-16.57%-15.78%-60.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
1.2506 of 5 stars
3.32.00.00.02.70.00.0
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
4.2859 of 5 stars
3.85.00.03.92.20.80.6
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
1.5288 of 5 stars
3.50.00.00.02.20.00.6
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
0.6397 of 5 stars
0.04.00.00.00.91.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
2.50
Moderate Buy$25.002,280.95% Upside
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
3.50
Strong Buy$13.171,096.97% Upside
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
3.00
Buy$21.00222.09% Upside
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CNSP, MRKR, NEUP, and TRIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/1/2025
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
WBB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy$12.50 ➝ $12.50
3/25/2025
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
3/5/2025
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/A($35.66) per shareN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$6.59M1.89N/AN/A$1.58 per share0.70
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
$15.66M0.78N/AN/A$7.82 per share0.83
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
$61.56M0.19N/AN/A($3.14) per share-0.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$18.85M-$3,748.50N/AN/AN/AN/A-515.32%8/12/2025 (Estimated)
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$8.24M-$1.33N/AN/AN/A-179.74%-89.63%-71.62%8/13/2025 (Estimated)
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
-$15.49MN/A0.00N/AN/AN/AN/AN/AN/A
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
-$24.02M-$2.82N/AN/AN/A-34.39%N/A-21.37%5/29/2025 (Estimated)

Latest CNSP, MRKR, NEUP, and TRIB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2024
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
-$0.28-$1.14-$0.86-$0.76$16.50 million$15.86 million
5/20/2025Q3 2025
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
-$0.47$6.55+$7.02$6.55N/A$15.00 million
5/15/2025Q1 2025
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A-$1.58N/A-$1.58N/AN/A
3/31/2025Q4 2024
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$0.28-$0.42-$0.14-$0.42$5.25 million$1.22 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/AN/A
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
N/AN/AN/AN/AN/A
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
$0.2234.69%N/AN/A N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A
1.82
1.82
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/A
3.15
3.15
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
N/A
2.06
3.30
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
N/A
1.64
0.87
CompanyEmployeesShares OutstandingFree FloatOptionable
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
52.94 million57.45 millionNot Optionable
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
6011.32 million9.16 millionNot Optionable
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
N/A1.88 million1.75 millionN/A
Trinity Biotech plc stock logo
TRIB
Trinity Biotech
48018.05 million16.57 millionOptionable

Recent News About These Companies

Trinity Biotech receives non-compliance notice from Nasdaq
Trinity Biotech zeroes in on CGM
Trinity Biotech announces additional funding for transformation plan

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNS Pharmaceuticals stock logo

CNS Pharmaceuticals NASDAQ:CNSP

$1.05 -0.03 (-2.78%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$1.08 +0.02 (+2.38%)
As of 05/28/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Marker Therapeutics stock logo

Marker Therapeutics NASDAQ:MRKR

$1.10 -0.05 (-4.35%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$1.10 +0.00 (+0.09%)
As of 05/28/2025 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Neuphoria Therapeutics Inc. - Common Stock stock logo

Neuphoria Therapeutics Inc. - Common Stock NASDAQ:NEUP

$6.52 -0.22 (-3.26%)
As of 05/28/2025 03:51 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Trinity Biotech stock logo

Trinity Biotech NASDAQ:TRIB

$0.63 -0.04 (-5.57%)
Closing price 05/28/2025 03:57 PM Eastern
Extended Trading
$0.67 +0.04 (+6.13%)
As of 05/28/2025 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.